Dr John Campbell
Dr John Campbell
@campbellteaching·3.3M subscribers·3.1K videos

New research game changer

Posted

November 13, 2020

Views

278,631

Likes

14,254

Comments

2,711

Engagement

6.09%

Search the Record

Indexed

Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.

Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.

Try a name, a topic, or a quoted line

YouTube Description

as posted by the channel

OpenSAFELY

New secure analytics platform

Electronic health records in the NHS

Created to deliver urgent results during the COVID-19 emergency

Analyses across more than 24 million patients

Full pseudonymised primary care NHS records

More to follow shortly

Open for security review

Scientific review

Secure environments

Trusted analysts

Large scale computation

Near real-time

Analyses in just five weeks from project start.

More accuracy than any previous analyses by an order of magnitude

Big data

Primary care data

Sufficient statistical power

Associations with specific medications and medical conditions

Early during the pandemic

Save lives by modifying patient, clinician, and population behaviour

Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform

Lancet, 5th November, MRC

)303787/fulltext

Hydroxychloroquine

Pre¬exposure (as opposed to post¬exposure) prophylactic

Inhibit entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into epithelial cells in vitro

No evidence of reduced mortality when treating patients with COVID-19

Methods

Observational

Population-based cohort study

Approximately 40% of the general population in England

Association between ongoing use before COVID-19

Compared with non-users of hydroxychloroquine

Risk of COVID-19 mortality

People with rheumatoid arthritis or systemic lupus erythematosus

n = 194, 637 with rheumatoid arthritis or systemic lupus erythematosus

n = 30, 569 received two or more prescriptions of hydroxychloroquine

March 1 and July 13, 2020

547 deaths

Users (n= 30,569)

70 deaths

IFR = 0.23%

Non – users (n = 164,068)

IFR = 0.22%

An absolute difference of 0·008%

Accounting for age, sex, ethnicity, use of other immunosuppressive drugs, and geographical

region

No association with COVID-19 mortality was observed

If you would like to donate to this educational project, please use the following link, thank you,

Guests & Subjects Covered

OpenSAFELY NewNHS CreatedNovember MRC Hydroxychloroquine PreexposureCOVID- Methods Observational Population-basedEngland AssociationCOVID- Compared

Sentinel Indexing in Progress

Metadata and chapters are available. Claim extraction for this episode is pending.

All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.

New research game changer · Dr John Campbell · Sentinel